This year's J.P. Morgan Healthcare Conference brought a bevy of news announcements — from acquisitions to partnerships to new products and more. This list compiles short summaries for seven of the event’s most notable announcements.
Medical device giant Boston Scientific added to its string of recent acquisitions by announcing its plan to buy Axonics, a maker of neurostimulation devices that treat urinary and bowel dysfunction, for $3.7 billion. Experts agree that this deal will make a profitable impact on Boston Scientific’s urology business.
Alan Murray on improving access for medical transportation.
A study published in August found that women experienced more adverse events from Boston Scientific’s Watchman implant than men. The FDA said it plans to take a closer look at data for these stroke-prevention implants, but still says the benefits outweigh the risks.
Abbott Laboratories received FDA approval for its Amulet device to treat people with atrial fibrillation who are at risk of ischemic stroke. The device would go head-to-head with one developed by Boston Scientific that was approved in 2015.
Boston Scientific will acquire remote cardiac monitoring company Preventice for $925 million in cash and up to $300 million in milestone payments. The deal is expected to close in mid-2021.
Earlier this year, the Marlborough, Massachusetts-based medical device giant invested $90 million into Millipede with the option of acquiring the rest of the company,
AI-native tax firm Gelt combines top human tax experts with AI to help physicians and healthcare practices use data-driven tax strategies to lower liabilities, improve profitability, and future-proof their finances.
Along with Boston Scientific's Watchman in the technology category, Novartis and Gilead's Kite shared the biotechnology award for CAR-T therapy, while Celgene/Agios's Idhifa won the pharmaceutical prize.
Boston Scientific's neurostimulation device Vercise is built on cochlear implant technology, allowing it to modulate impulses between multiple contacts.
Medtronic becomes the first in the U.S. to win FDA approval for a quadripolar cardiac resynchronization therapy pacemaker that is also safe to use under MRI if certain conditions are met.
Boston Scientific may have purchased Swiss structural heart company Symetis for many reasons but one could very well be that the Lotus aortic valve is not ready for prime time.
In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers play.
If one were to believe the device lobby, jobs would come roaring back once the device tax is permanently repealed. The reality is more complex.
Boston Scientific is testing microspheres coated with a chemotherapy drug that can be delivered at the tumor site in the liver to provide an alternative to chemotherapy drugs with its attendant side effects and costs.
Cosman Medical, which makes RF generators and electrodes among other things, will become part of Boston Scientific's neuromodulation business.
With the full ImageReady system, patients are approved to get full-body MRI scans, which eliminates some of the potential risks of a device malfunctioning due to the scan.
The AXIOS Stent and Electrocautery Enhanced Delivery System is designed to help physicians manage serious complications from pancreatitis using a minimally invasive endoscopic approach.